LREM MP Olivier Véran will propose an amendment, for the experimentation of medical therapeutic cannabis for two years, as part of the vote for the Social Security financing bill. During the summer, the ANSM has already given the green light for an evaluation.
Will therapeutic cannabis soon be authorized in France? The deputy for Isère Olivier Véran announces that he will propose an amendment to the Social Security financing bill to authorize the experimentation of this type of use. The trials should begin in January 2020 for a duration of two years.
Experimenting with the medical use of #cannabisit will be:
? 3000 patients
? on specialist prescription
? for specific indications such as cancer pain
? for 2 years with evaluation
This is the purpose of my amendment to #PLFSS2020 pic.twitter.com/y6bBJKGcnX— Olivier Veran (@olivierveran) October 9, 2019
“A complementary therapeutic contribution”
“France is one of the last countries in the European Union not to have authorized it”, launched the LREM deputy on RTL, Wednesday, October 9. According to him, thousands of patients with serious illnesses would benefit from therapeutic cannabis. “Cannabis derivatives can constitute an additional therapeutic contribution”, specified the elected official. During the two-year trial, approximately 3,000 patients are expected to participate. The experiment will be strictly supervised and reserved for specific cases, such as cancer pain. “We are not talking to a 16-year-old teenager who goes out for a party with cannabis resin, smokes and shoots his memory system and takes the risk of having mental disorders, said defended the member, we are talking about a patient who has cancer or neuropathic pain, who is at a therapeutic impasse, no longer lives, no longer eats, no longer sleeps, no longer takes care of his children, no longer has a quality of life and says to you: I’ve been self-medicating like this for a year and I’m better. Accompany me, rather than leaving me illegally.” At the end of the two years, assessments will be carried out to determine whether the use of cannabis in a medical setting is relevant.
The green light from the ANSM in July
Last July, the National Agency for the Safety of Medicines (ANSM) validated the experimentation of cannabis for therapeutic use. The product should be prescribed as an inhalation or oral solution. In no case will it be a “joint on prescription”.
.
